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Background:   Activation of the sympathetic nervous system (SNS) in response to chronic biobehavioral  stress  results  in  high  levels  of  catecholamines  and  persistent  activation  of adrenergic  signaling,  which  promotes  tumor  growth  and  progression.  However  it  is unknown how catecholamine levels within the tumor exceed systemic levels in circulation. I  hypothesized  that  neo‐innervation  of  tumors  is  required  for  stress‐mediated  effects  on tumor growth. 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1. Rationale and Significance   Modern science has demonstrated that biobehavioral factors can affect disease  states.    This  interaction was  coined  the  “mind‐body” model  of  illness  by psychiatrist  George  Engel  (1).  Since  then,  experimental  and  clinical  evidence  has shown  that  psychological  factors  can  affect  several  types  of  diseases,  including cardiovascular  disease  and  cancer.  Altered  mental  and  physical  states,  such  as depression or  stress,  activate  the  sympathetic nervous  system and hypothalamic‐pituitary‐adrenal  axis  to  cause  release  of  hormones,  including  catecholamines.  Recent  evidence  has  shown  that  catecholamines  are  capable  of  promoting  tumor growth and progression (2) through increases in tumoral catecholamine levels (3). We  sought  to  find  a  link  between  chronic  stress  and  the  high  levels  of catecholamines  seen  within  tumor  tissue.  Catecholamines  may  be  released  into circulation  by  the  adrenal  gland  or  locally  by  sympathetic  nerve  endings.    I hypothesized that sympathetic neurons within the tumor would be responsible and that chronic stress would be capable of inducing growth of these neurons into the tumor.    My  work  demonstrates  1)  nerve  density  in  tumors  from  chronically stressed  animals  is  increased  compared  to  non‐stressed  controls;  2) Norepinephrine  signals  through  the  β3‐arenergic  receptor  to  stimulate  BDNF production  in  tumor  cells which  is  then  responsible  for  promoting  nerve  growth into the tumor; 3) high nerve density is associated with high BDNF expression and poor  outcome  in  ovarian  cancer  patients.  Together  these  data  represent  the  first demonstration  that  tumors  are  capable  of  promoting  neo‐innervation.  It  also demonstrates  that  neo‐innervation  of  tumors  is  required  for  chronic  stress‐
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mediated  tumor  progression.  This  work  provides  evidence  that  BDNF  may  be  a viable  therapeutic  target  in  chronically  stressed  patients  in  order  to  block  the deleterious effects of chronic stress on patient outcome. 
 




3. The Stress Response   In  a  healthy,  non‐stressed  individual,  the  body’s  homeostasis  is maintained  through  a  balance  between  virtually  every  system  in  the  body.    Each system runs at counterbalance to the others at normal basal levels to keep the body healthy  and  functional.    As  shown  in  Figure  1A,  the  sympathetic  and parasympathetic nervous systems (SNS and PSNS, respectively) act as opposites to regulate many body functions. Stress, however, causes a disruption in this balance. The  catecholamines  of  the  sympathetic  nervous  system  overbalance  and  cause hyperactivation  of  critical  systems,  vasoconstriction,  and  overall  heighten  the body’s capability of dealing with a perceived stressor.  In the case of chronic stress, the  body  remains  in  this  constant  state  of  hyper‐activation  and  awareness,  and eventually results in a multitude of health issues    Stress  is  an  extremely  complex  process  that  has  widespread  and diverse effects throughout the body, ranging from cardiovascular effects to changes in  gastrointestinal  function  and  immunity.    Once  the  body  detects  a  stressor,  the central nervous system (CNS) activates both the autonomic nervous system (ANS) and the hypothalamic‐pituitary‐adrenal axis (HPA).  Stimulation of the ANS results in  activation of  the  sympathetic nervous  system  (SNS)  and  subsequent  release of catecholamines.    Among  other  functions,  Norepinephrine  (NE)  and  epinephrine control  blood  pressure  and  heart  rate.    They  act  as  vaso‐constrictors,  increasing blood  pressure,  and  increasing  blood  flow  to  organs  critical  to  the  fight  or  flight 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stress  response.    The  third  catecholamine,  dopamine,  is  involved  in  learning, sociability,  and  promoting  reward‐seeking  behavior  (6).  Its  release  is  used  to control  levels  of  prolactin,  which  has  numerous  functions  in  the  body,  from reproduction to neurological function and immunity (7).    Activation  of  the  HPA  axis  causes  release  of  corticotrophin  releasing hormone (CRH) from the hypothalamus, setting off a cascade that results in release of  glucocorticoids  from  the  adrenal  gland  (Figure  1B).    Receptors  for  these hormones  are  found  on  virtually  every  cell  type.    In  normal  physiology, glucocorticoids  are  responsible  for  regulating  immunity,  cardiovascular  function, and metabolism, among others (8, 9). Under stress conditions these hormones are responsible  for  the  defeat/withdrawal  response.  Under  chronic  stress  conditions they cause prolonged inhibition of CRH and subsequent inhibition of immunity.     Stress  responses  are  highly  adaptive  systems  that  affect  not  only physiological  changes,  but  also  behavioral  and  neurological  systems.    Combined, these  changes make up  the  collective  “stress  syndrome.” First,  the body prepares for its best chance of survival by shutting down physiological functions that are not immediately  deemed  essential,  and  reroutes  those  resources  to  more  critical functions.  For example, following detection of a stressor the body slows digestion and  growth  as  well  as  inhibits  immune  function  and  stalls  reproductive  urges.  Conversely, it increases cardiac output, respiratory rate, and energy production. 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4. Acute versus chronic stress   It is important to distinguish between the types of stress the body can experience.    Although  stressors  can  be  physical,  mental,  emotional,  social,  or biological,  a  critical  distinction  is  whether  the  stress  is  acute  or  chronic.    Acute stressors  are  short‐lived,  infrequent,  and beneficial  to  the body.   A good example would be an individual giving a public speech or taking a test.   Following an acute stressor  the  body  prepares  by  releasing  catecholamines  and  glucocorticoids  to increase blood flow and prepare the body to cope.   Once the stressor  is removed, the stress response systems return to baseline and normal function resumes.      On the other hand, chronic stressors recur frequently or are sustained over  long  periods  of  time,  typically  from  months  to  years.    Good  examples  of chronic  stressors  are  depression,  chronic  fatigue,  a  feeling  of  isolation  or  poor social support, or even  the daily strain of a stressful  job.   While chronic stressors activate the same pathways as acute stressors, their continual or persistent nature does not allow these systems time to shut off, leaving the body in a constant state of overdrive.    This  continual  response  causes  a  prolonged  disruption  of  the  body’s homeostasis  as  it  attempts  to  cope.    Over  time  this  increases  risk  of  several diseases,  most  particularly  cardiovascular  disease,  and  has  been  associated  with 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disruptions  in  metabolism,  reproduction,  immune  activity,  and  even  cancer initiation (11‐13). 
 
5. Chronic stress impacts on disease  
A. Chronic stress and Cardiovascular disease   Effects of chronic stress on the cardiovascular system are perhaps the most well‐studied and characterized. This link has been investigated for more than six  decades,  and  has  shown  from  virtually  every  angle  that  psychological  and biobehavioral factors play a major role in promoting cardiovascular disease.  These studies show that psychological factors can cause myocardial infarctions, coronary heart disease, hypertension, atherosclerosis, and other cardiovascular health issues (14).   For example, studies have demonstrated  that even short periods of chronic stress  can  increase  risk  of  cardiovascular  problems  decades  later  (15).  Large epidemiological  studies  have  correlated  feelings  of  irritability  or  anxiety  with increased incidence of myocardial infarctions (16).     Effects of chronic stress on risk of cardiovascular disease are primary a result  of  increased  levels  of  cortisol  and  catecholamines.  Catecholamines  signal through adrenergic receptors (ARs), primarily the β‐family of adrenergic receptors (ADRB)  (see  section  7B  below).  As  a  result,  many  patients  with  cardiovascular disease are treated with β‐blockers, a class of drugs that inhibits catecholaminergic activation of β‐ARs, resulting in lower blood pressure and heart rate. 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B. Chronic stress and immunity   Chronic  stress  effects  on  the  immune  system  are mediated  primarily through activation of  the HPA axis and release of glucocorticoids, as well as some control  through  the ANS and catecholamines.   Several  studies have demonstrated interactions  between  the  CNS,  endocrine,  and  immune  systems,  and  suggest  that disruption to one system will have subsequent effects on all.      The  dual  nature  of  glucocorticoids  in  acute  versus  chronic  stress  is highly pertinent to immune function.   Normal physiologic levels of glucocorticoids are  immunoregulatory,  maintaining  normal  immune  surveillance.  Chronic  stress significantly  increases  levels  of  glucocorticoids,  at  which  point  they  become immunosuppressive.    Within  the  immune  system  T  and  B  cell,  neutrophils, monocytes,  and macrophages  all  carry  glucocorticoid  receptors.    This  allows  for chronic  stress  to  disrupt  both  cellular  and  humoral  immune  responses,  such  as inhibiting  inflammation,  causing  a  shift  in  the  balance  between  Th1  and  Th2 cytokines, and causing antigen‐presenting cells to cease production of IL‐12, all of which are important for immune adaptation (17,18). High levels of glucocorticoids can also cause apoptosis in monocytes, macrophages, and T lymphocytes (19).   
 
C. Chronic stress and the central nervous system   Chronic stress can also have significant effects on neurological function.  Specific  brain  regions  (notably  the  hippocampus)  express  high  densities  of glucocorticoid  receptors.    Chronic  stress  levels  of  glucocorticoids  can  therefore 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have  very  prominent  effects  on  memory,  both  through  interfering  with  new memory  formation  (20,21),  as well  as  in preventing  access  to  existing memories.  For  example,  hippocampal  function  is  significantly  reduced  following  chronic stress,  and  several  studies  support  that  this  is  due  to  dendritic  retraction of  CA3 neurons,  ultimately  resulting  in  impaired  special  memory  (22).    Additionally, chronic stress  is known to impair neurogenesis  in the dentate gyrus region of the hippocampus,  thereby  impairing  new memory  formation  and  increasing  anxiety‐like responses (23).  
6. Chronic stress and cancer (Figure 2)   More  recent  studies  have  demonstrated  that  chronic  stress  has  a pronounced impact on virtually every facet of cancer, from playing a role in cancer initiation to promoting tumor growth and metastasis through several mechanisms.  These studies have looked at both animal models of chronic stress as well as human clinical data.    
A. Animal models of chronic stress   Several  different  methods  have  been  used  to  mimic  the  effects  of psychosocial  stress  in  laboratory  animals.    Methods  have  included  swim  stress, hypothermia, rotation, restraint, social isolation, and social domination. Our group routinely uses the restraint stress model. Studies have demonstrated that physical restraint stress causes modulations in levels of both catecholamines and 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glucocorticoids  (2,  24).    We  have  found  that  chronic  restraint  stress  increased tumor  growth,  and  exhibited  higher  tumor  levels  of  catecholamines  and glucocorticoids,  suggesting  that  this  model  activates  both  the  HPA  axis  and sympathetic  nervous  system,  and  therefore  functions  as  a  good  model  for mimicking chronic psychological stress in humans (2, 24).   
B. Chronic stress and cancer initiation   Human  tumorigenesis  is  a  complex, multistep  process.    Hanahan  and Weinberg  postulated  that  six  steps  are  required  for  transformation  of  cells:  self‐sufficiency  in  growth  signals,  insensitivity  to  antigrowth  (growth  inhibitory) signals,  evasion  of  programmed  cell  death  (apoptosis),  limitless  replicative potential,  sustained  angiogenesis,  and  tissue  invasion  and  metastasis  (25). Evidence  that  chronic  stress may play  a  role  in promoting  this  transformation  is, however,  difficult  to  reconcile  due  to  often  contradictory  results.  Two  separate clinical  studies  have  been  performed  on  women  following  identification  of  a suspicious lesion, and prior to diagnosis by biopsy.  The first of these studies found a significant correlation between malignant  lesions and  the occurrence of at  least one major stressful life event in the previous 5 years (26).   Conversely the second study concluded that day‐to‐day stress actually decreased risk of breast cancer by as much as 40% (27).   The confounding results demonstrated by these studies as well as others may be the result of variations  in statistical analysis, differences  in methods of determining stress, and the  inability  to differentiate whether stress  is actually causing cancer or whether its role is more important for progression of a 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tumor to a malignant lesion.  Additional difficulties arise in that these studies are all epidemiological,  retrospective  studies.  A  long‐term  longitudinal  epidemiological study may  be  needed  to more  effectively  elucidate  the  involvement  that  chronic stress has on tumor  initiation; however no such study has been done, most  likely due to restraints such as feasibility and cost.  It is also difficult due to the fact that there  are  very  few  ways  of  mimicking  this  process  in  pre‐clinical  models,  and similar restraints exist to prevent the feasibility of any such model.   To date, very few  studies  have  demonstrated  solid  biological  mechanisms  that  may  suggest chronic stress can initiate tumor formation, though those that exist seem to indicate it  is  through  enhancement  of DNA damage.  Glaser  et  al  demonstrated  that  stress can impair DNA repair through downregulation of the ciritcal DNA repair enzyme Methyltransferase  (28).  Hara  et  al  also  demonstrated  that  stress  enhances  DNA damage through activation of β‐arrestin‐1 (29).  
7. Stress and cancer progression   In  the  last  few  decades,  there  have  been  significant  data  supporting chronic  stress  effects  on  cancer  progression  from  both  preclinical  and  clinical settings.    Clinically,  chronic  stress  has  been  associated  with  poorer  outcome  in cancer patients (30‐34). Preclinical evidence has demonstrated that chronic stress can  promote  cancer  progression  through  increased  angiogenesis,  invasion,  and migration leading to metastasis, cell survival, and immune escape. 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A. Stress, Immunity, and cancer progression   There  are  a  significant  amount  of  data  supporting  the  role  of  chronic stress  in  suppressing  the  immune  system  to  allow  tumors  to  progress.    As previously  mentioned,  chronic  stress  causes  a  shift  in  immune  function.    Stress hormones  inhibit  cellular,  or  Th1,  immunity,  allowing  tumor  cells  to  evade surveillance.  Stress  inhibits  release  of  pro‐inflammatory  cytokines,  impairing maturation  and  tumor  eliminating  capacity  of NK  cells,  T  cells,  and macrophages (35). Epinephrine and prostaglandin, two hormones that increase following chronic stress,  were  found  to  promote  progression  of  leukemia  by  suppressing  NK  cell activity (36). Clinically, patients with poorer social support had lower levels of anti‐tumorigenic  cytokines  and  increased  IL‐4,  which  indicates  poorer  immune‐mediated clearance of tumor cells (37).  Additionally, tumor‐infiltrating leukocytes (TILs)  demonstrate  increased  type‐2  immune  response,  which  is  generally considered  pro‐tumorigenic  (38‐41).  Poor  social  support  has  also  been  seen  to reduce  NK  cell  activity  (42‐43).  Catecholamines  have  been  shown  to  have  a significant effect directly on  immune activity.    Inhibition of SNS activity promotes adaptive  immunity  through  increases  in  Th1  immunity  (44).  Cunnick  et  al demonstrated that adrenalectomy recovered T‐cell responses previously inhibited by stress (45).   
B. Stress and adrenergic signaling in cancer   Effects  of  catecholamines  are mediated  through  adrenergic  receptors (ARs). This family of 7‐transmembrane G‐coupled receptors consists of a total of 8 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receptors divided into α and β sub‐families (46). Several studies have found these receptors  to be expressed on a variety of  tumor  types, with  increased expression found in several cancers such as oral, liver, and colon (47‐50). G‐coupled receptors act  as  molecular  switches  to  control  a  diverse  array  of  downstream  signaling pathways,  and  have  been  found  to  contribute  to  several  pathways  of  tumor initiation  and  progression.  These  receptors  have  a  dichotic  function,  acting something  like on/off  switches  for  their downstream signaling.   Binding of  the Gs subunit  results  in  activation  of  downstream  pathways,  while  binding  of  the  Gi subunit inhibits signaling.     When  members  of  the  ADRB  family  are  activated,  they  initiate downstream  signaling  through  the  cAMP/PKA  and  Epac  signaling  pathways.  Downstream  of  PKA  signaling  can  activate  the  cAMP  Response  Element  Binding (CREB) protein which can activate a wide array of human genes, many of which are crucial to tumor growth and migration (51‐52).  Signaling through Epac (Exchange Protein activated by Adenylyl Cyclase) activates the MAP Kinase signaling pathway, which is well known to have potent effects promoting tumor proliferation.     
C. Neuroendocrine effects on tumor cell proliferation   Cell  growth,  proliferation,  and  survival  are  controlled  through  a balance between positive and negative signals. Stress hormones can interfere with this  balance  (53).    Studies  have  shown  conflicting  evidence  for  neuroendocrine 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impact  on  tumor  cell  proliferation.    For  instance,  several  studies  have  found  that adrenergic activation inhibits tumor cell proliferation, while others suggest it may enhance cell proliferation. One group found that ADRB2 signaling was required for pancreatic cell survival, and that blockade of ADRB2 induced cell apoptosis through the  NFkB  pathway  (54).  Conversely,  another  group  found  that  NE  treatment  of breast cancer cells stimulated proliferation through an α2‐AR specific pathway, and that use of an ADRB agonist countered this effect and decreased proliferation (55). Yet  another  group  found  that  NE  treatment  inhibited  proliferation  of  mouse chondrocytes  through  the  ADRB2  receptor  (56).  Perhaps  one  could  argue  that response  is  simply  cell‐type  specific,  and  depends  largely  on  which  adrenergic receptor family members are expressed on the cell.      Although  the  impact  of  adrenergic  activation  on  proliferation  is conflicting, the vast majority of studies all agree that chronic stress promotes tumor growth.   This begs  the question,  if  adrenergic activation  is not promoting growth through  cell  proliferation,  then which mechanisms  are  being modulated?  Studies from our group and others show that  it  is  in  fact  through promoting cell  survival and inhibition of apoptosis.     
D. Adrenergic influences on tumor cell survival   Tumor cells must adhere  to extracellular matrix  (ECM) compounds  in order to metastasize and to avoid anoikis (Greek for “homelessness”). As previously 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lesions.    It  is  therefore  important  to  understand  how  a  tumor metastasizes,  and how chronic  stress  can promote  this process.   Metastasis  is  a  complex process  in which  the  cells must  sequentially  gain  several  characteristics  or  the  cascade  fails (63) (Figure 3). First, a developing tumor must develop a blood supply, as nutrients and  oxygen  from  the  bloodstream  are  only  capable  of  diffusing  <1  mm  through tissues.  This  also  provides  a  direct  route  for  metastasis  of  cancer  cells  to  other locations in the body. Secondly, tumor cells must be capable of detaching from the main  tumor,  secreting  enzymes which  break  down  the  basement membrane  and allow  embolization  into  the  blood  stream.  Once  the  cell  becomes  entrapped  in  a capillary bed,  it must then be capable of extravasation from the blood stream and begin to grow in the new tissue bed, at which point the cycle begins again, and the new tumor must establish its own blood supply.  During every step of this cycle the tumor  cells must  also  be  capable  of  avoiding  surveillance  of  the  immune  system (64).  Increasing  evidence  shows  the  stress  response  can  affect  many  of  the processes in this cascade.     








 Several factors may be responsible for promoting growth of blood vessels.  There is a great deal of  literature describing the effects of stress on two potent angiogenic factors, Vascular Endothelial Growth Factor (VEGF) and Interleukin‐6 (IL‐6).    Norepinephrine  has  been  shown  to  increase  production  of  VEGF through activation of  β‐AR/cAMP/PKA  signaling  (65), which  can be mimicked by isoproterenol  (a  β‐agonist)  and  blocked  with  β‐blockers  (66).  In  animal  models norepinephrine  increased  CD31  positive  staining,  representing  an  increase  in vessel density and therefore angiogenesis (66). In patients, high social support was associated with lower levels of VEGF (67).      IL‐6 is a pro‐inflammatory cytokine.  Although its primary function is in immunity,  IL‐6  also  plays  a  role  in  promoting  angiogenesis.  Under  chronic  stress conditions,  IL‐6  expression  is  increased  in  tumor  cells  through  adrenergic activation of Src signaling (68). Clinical evidence has shown that patients with poor social  support  have  higher  levels  of  IL‐6  when  compared  to  patients  with  good social  support  (69)  and  these  high  levels  are  associated with  poorer  outcome  in patients (70).   
G. Adrenergic impact on migration and invasion of tumor cells   Tumor  cells  must  gain  the  ability  to  migrate  and  invade  to  become metastatic.    Chronic  stress  has  been  shown  to  promote  tumor  cell  migration  in breast  and  ovarian  cancer  cells  through  activation  of  β‐adrenergic  receptors 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(66,71).  Chronic  stress  also  promotes  tumor  cell  invasion  through  activation  of several  promalignant  pathways.    This  invasion  is  primarily  mediated  through activation  of  STAT3  signaling,  which  promotes  invasion  through  increasing expression  of  MMP‐2  and  ‐9,  both  of  which  play  a  critical  role  in  degrading  the basement  membrane  and  allowing  tumor  cells  to  invade  the  vasculature  and thereby travel to metastatic sites (66,72‐73).   
8. Clinical impact of chronic stress   Several studies have now been done to investigate the possible patient benefit  of  psychological  interventions.    However,  there  is  a  great  deal  of controversy  over  the  studies  that  have  been  done with  psychological/behavioral interventions.    For  instance,  many  studies  have  looked  only  at  so‐called  “soft” factors,  such  as  quality  of  life  and  feelings  of  well‐being,  as  opposed  to  “hard” factors,  such as survival and cortisol  levels, which a concrete value can be placed upon.    Perhaps  the  most  convincing  of  these  studies  was  done  at  Ohio  State University. The group performing these studies found that placing patients in small support groups resulted  in decreased anxiety,  improved social  support,  improved immune  response,  and  overall  improved  health.    Follow‐up  of  11  years  on  these patients  also  revealed  that  patients  who  participated  in  the  groups  had  reduced chance  of  both  recurrence  and  death  (74‐76).  Other  studies  have  found  that psychological  interventions  reduce  cortisol  levels,  improve  immune  response (through  measures  of  lymphocyte  proliferation),  and  provide  patients  with  an 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overall  improved  feeling  of  well‐being  (77‐80).  These  studies  suggest  that behavioral therapies may be a viable option for improving patient quality of life as well as outcome, and merit further investigation.     Most of the preclinical studies of chronic stress effects on cancer have shown these effects to be mediated primarily through the β‐family of adrenergic receptors.  As such, β‐blockers have been of interest for clinical use.  To this point, most of the studies have been either retrospective or have contained confounding factors.  For example, a retrospective study looked at the risk of developing prostate cancer  in patients  taking  β‐blockers,  and  found  that  these  patients  had  significantly  lower risk  (81). Another  retrospective  study  looked at overall  risk of  cancer  in patients taking β‐blockers for cardiovascular disease, and found that these patients also had reduced overall risk of developing cancer (82).  Further observational studies have demonstrated  improved  relapse‐free  survival,  secondary  tumor  formation,  and overall  mortality  in  breast  cancer  (83‐84)  as  well  as  improved  outcome  in melanoma  (85‐86).  No  clinical  trials  have  yet  been  performed  to  determine  the efficacy of these drugs in treating a patient’s cancer, however.  
9. Neurogenesis 
 
A. Embryonic neurogenesis   Development  of  peripheral  neurons  during  embryogenesis  is  a  fairly well‐understood  process.    Neurons  originate  in  the  neural  crest  from 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sympathoadrenal  progenitor  cells  (87).  These  cells  quickly  begin  migrating ventrally and begin differentiating into catecholaminergic neurons.  There is then a period  of  cell  death  that  results,  as  neurons  are  initially  produced  in  excessive numbers.    This  period  is  controlled  by  neurotrophic  factors,  primarily  Nerve Growth  Factor  (NGF)  and  its  family members,  Neurotrophin‐3  (NT‐3)  and  Brain derived  neurotrophic  factor  (BDNF)  (88‐89).    NGF  and  NT3  signaling  through Tyrosine  receptor  kinase A  (TrkA) maintain  survival  and  direction  in  developing neurons  (90‐91).    Conversely,  signaling  through  the  p75NTR  receptor  can  lead  to apoptosis of neurons (92)  in  the absence of Trk receptor activation (93) or when co‐activation  of  Trk  and  p75  receptors  shifts  in  favor  of  p75.  Once  activated  by neurotrophins, the internal domain of p75 activates ceramide production leading to cell death (93‐94).  Most neuronal circuits track along blood vessels.  Some studies suggest that this may be a result of the high amounts of NT‐3 and moderate levels of  NGF  secreted  by  vessels  (95‐97),  which  may  provide  growth  advantages  and direction as these circuits are developing.    
B. Adult Neurogenesis and nerve growth In  human  adults,  neurogenesis  has  previously  been  thought  to  occur  in  only  two specific brain regions: the subventricular zone of the forebrain (98) and the dentate gyrus  region  of  the  hippocampus  (99)  (Figure  4).    More  recent  studies  are beginning to demonstrate that neurogenesis can also take place in other regions of the  brain,  suggesting  that  this  process may  be more widespread  than  previously thought  (100‐102).  In  adult  CNS  neurogenesis,  maturing  neurons  are  able  to 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C. Doublecortin During neuronal maturation, precursors express several different markers, some  of which  fade  as  the  neurons mature,  others  of which  increase  throughout maturation.    One  of  these  markers  is  doublecortin  (DCX)  protein.    Found  in  all neural  progenitor  cells  and  neuroblasts,  doublecortin  is  frequently  used  as  a marker  of  adult  neurogenesis.    As  neurons  mature  and  differentiate,  DCX expression decreases rapidly, as expression of mature neuronal markers increase.  Expression is usually completely absent after about 14 days (Figure 4).   Brown et al.  first  demonstrated  use  of  DCX  as  a  marker  for  adult  neurogenesis  due  to  its transient expression (105).   The high expression levels in new neurons, and quick fading as more mature neuronal markers increase, makes this an ideal marker for newborn neurons (105)  














   Interestingly, several studies have implicated BDNF expression as an important factor in stress‐induced impairment of neurogenesis in the CNS.  Under conditions of  chronic  stress, BDNF expression  is downregulated  in neurogenic brain  regions (108‐109)  by  histone methylation  (121)  and  corticosterones  (122).    In  contrast, very  recent  studies  have  demonstrated  that  chronic  immobilization  (restraint) stress  induces  dendritic  growth  in  the  amygdala  (123).  Perhaps most  interesting was a  study by Lakshminarasimhan and Chattarji  that demonstrated  that  chronic restraint  stress  not  only  caused  dendritic  atrophy  in  the  hippocampus  and dendritic  growth  in  the  amygdala,  but  that  this  also  correlated  with  significant decreases in BDNF in the hippocampus and increases in the amygdala (124_.  These exciting  data  demonstrates  that  stress  may  play  contrasting  roles  on  neuron growth through modulations in BDNF.   
B. Nervous system impact on tumor progression The  connection  linking  the  nervous  system  and  tumor  growth  has  been relatively  little  studied.   While many  groups  have  demonstrated  the  presence  of nerves in tumors, hypotheses on their function and origin have, to this point, been weak  and  highly  correlative.    Work  done  by  several  different  groups  has demonstrated  that  various  tumor  types  secrete  neurotrophic  factors,  and  that media  conditioned by  these  cells  is  capable  of  inducing neurite  outgrowth  (125).  However, no direct mechanism has been demonstrated. Additionally, many studies have  demonstrated  that  neurotransmitters  are  capable  of  influencing  tumor 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Antibody  Provider  Catalog Number Neurofilament (anti mouse)  millipore  MAB1615 Neurofilament (anti human)  abcan  ab9035 BDNF  Abcam  ab72438 doublecortin  abcam  ab18723 tyrosine hydroxylase  millipore  mab318 CD31  PharMingen    GFP  abcam  ab13970 RFP  abcam  ab62341 anti mouse HRP IgG1  Jackson Immunoresearch    anti mouse HRP IgG  Jackson Immunoresearch    anti rabbit secondary HRP  Jackson Immunoresearch    anti‐Rabbit Alexa 488  jackson Immunoresearch    anti‐Rabbit Alexa 594  Invitrogen    anti‐mouse Alexa 488  Invitrogen    anti‐mouse Alexa 594  Invitrogen    AMCA‐conjugated anti‐Rabbit  Jackson Immunoresearch  code 111‐156‐047 Hoechst  invitrogen     
Methods  Table  2.  Antibodies  used,  provider,  and  catalog  number  (where available).  Lipfectamine 2000 transfection reagent was purchased from Invitrogen (Carlsbad, CA).    Unless  otherwise  noted,  all  media  for  tissue  culture  were  obtained  from Invitrogen.    
2. Cell lines   The source and derivation of HeyA8, SKOV3, and A2780 ovarian cancer cells has  previously  been  reported  (2).    Cells  were  grown  in  RPMI  medium supplemented with  15%  fetal  bovine  serum  and  0.1%  gentamicin  sulfate.    PC12 cells were  a  kind  gift  from Dr.  Yixin  Yao  and  its  derivation  and  source  has  been 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described  previously  (131).    These  cells  were  maintained  in  RPMI‐1640 supplemented with 10% horse serum and 5% fetal bovine serum.  Colon cancer cell lines were a kind gift from Dr. Lee Ellis and were maintained in MEM supplemented with NAA (Mediatech), sodium pyruvate (Gibco), Glutamine (Gibco), and 10% FBS.  Their  source  and  derivation  have  previously  been  described  (132).  Cells  were screened  for mycoplasma,  and  all  experiments were  carried  out while  cells were ~70% confluent unless otherwise noted.  
3. siRNA   SiRNA was used for gene expression knockdown both in vitro and in vivo.  All siRNAs were obtained from Sigma‐Aldrich (St. Louis, MO).   Cells were transfected according  to manufacturer’s  protocol.  Briefly,  for  in  vitro  transfection  cells  were plated at 15‐20% confluency.  8 μg (10 cm) or 2 μg (6‐well) of siRNA was diluted in 100 μL serum‐free media and allowed to incubate for 5 minutes.  30 μL (10 cm) or 5 μL (6‐well) of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was also diluted in 100 μL serum‐free media and allowed to incubate 5 minutes.  Following incubation the diluted siRNA and transfection reagent were combined and allowed to incubate for 25 minutes before being added to cells.  Total volume was then brought up to 15 mL (10 cm) or 2 mL (6‐well) using serum‐free media.  The reactions were allowed to continue for 5 hours, at which point 15% fetal bovine serum was added to halt transfection. Knockdown efficiency was tested by qPCR at 24, 48, and 72 hours.  For all  siRNAs  tested 48 hours was  sufficient,  therefore  all  experiments were  carried out at 48 hours post‐transfection. 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 For in vivo studies, siRNAs were incorporated into 1,2‐dioleoyl‐sn‐glycero‐3‐phosphatidylcholine (DOPC), a neutral liposome delivery molecule extensively used by  our  lab  and  previously  described  by  (133).    Incorporations were  done  in  the laboratory of Dr. Gabriel Lopez‐Berestein as follows: DOPC and siRNA were mixed in the presence of excess tertiary butanol at a ratio of 1:10 siRNA:DOPC.  Tween 20 was  added  to  the mixture  in  a  ratio  of  1:19 Tween 20:siRNA/DOPC. The mixture was vortexed,  frozen  in an acetone/dry  ice bath, and  lyophilized.   Prior  to  in vivo administration, the lyophilized mixture was hydrated with 0.9% saline to 20 µg/mL concentration.    Animals were  treated  at  a  5 µg/mouse/treatment dose,  therefore 100 µL of the hydrated mixture was injected intra‐peritoneally into each mouse.    






 hours the wells were removed.  Media was removed using a vacuum manifold.  Cells were  fixed  in  ice‐cold methanol  for  20 minutes  then washed  in  PBS.    They were then  stained  in  neurite  stain  solution  (Millipore)  and  again  rinsed  in  PBS.    Once thoroughly  rinsed,  cell  bodies  remaining  on  the  upper  surface  of  the membranes were removed using cotton swabs and PBS.  The membranes were then allowed to dry overnight before being removed from inserts, placed on a microscope slide and coverslipped.    Five  40x  objective  fields  were  counted  per  membrane,  and  all treatments  were  done  in  duplicate,  for  a  total  of  10  fields  per  treatment  group.  Each  branch was  counted  as  a  separate  neurite  extension,  with  no  bias  given  to length or size of the extension.     
5. Conditioned media   For  experiments  requiring media  conditioned  by  ovarian  cancer  cell  lines, serum‐free media was used and all media remained on cells  for 24 hours prior to being  collected.    For  cells  that  were  treated with  norepinephrine,  the  cells  were serum starved overnight, and new media was added at the time of treatment. The conditioned  media  was  then  collected  24  hours  post‐treatment.    For  media conditioned by cells treated with siRNA, the cells were transfected at time 0, media replaced with serum‐free media at 48 hours post‐transfection, and collected at 72 hours  post‐transfection.    For  cells  treated  with  both  siRNA  and  norepinephrine (NE),  cells  were  serum‐starved  from  36‐48  hours  post‐transfection,  new  media containing  NE  given  at  48  hours,  and  collected  at  72  hours  post‐transfection. 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Conditioned media  from  each  treatment  group  was  used  for  subsequent  neurite extension assays.  




7. In vivo Models All  experiments  using  human  cell  lines  were  done  in  8‐  to  12‐  week  old female  athymic  nude  mice  received  from  Taconic  Farms  (Hudson,  NY).  Experiments  using mouse  cell  lines were performed  in C57/B6  lineage mice.    All experiments were approved by  the M. D. Anderson  Institutional Animal Care and Use Committee (IACUC)   


























9. Tumor cell inoculation To prepare tumor cells for inoculation, cells were plated and allowed to grow until 60‐70% confluent to ensure they were still in the exponential growth phase.  Cells were then washed and lifted using 0.25% trypsin/EDTA.  After lifting, trypsin was inactivated  using  media  supplemented  with  FBS.    Cells  were  spun  down  for  5 minutes at 1300 rpm, washed and resuspended  in Ca2+/Mg2+‐free Hanks Buffered Saline  Solution  (HBSS).    Cells  viability  was  tested  using  trypan  blue  and  then counted. The volume containing the desired number of cells was then removed and spun  down  again,  and  re‐suspended  in  HBSS  to  the  desired  concentration.  Injections  were  done  in  a  volume  of  200  μL  per  mouse  intraperitoneally.    Cell numbers used for injection were as follows:  
Cell line  Cell number injected SKOV3‐ip1  1 x 106 HeyA8‐ip1  2.5 x 105 RKO‐ip1  3 x 106 ID8‐VEGF  1 x 106   
10. In Vivo siRNA treatments SiRNA  treatments  began  on  day  5  following  tumor  cell  inoculation.    This time  lapse was  allowed  to  ensure  that  knockdown  of  the  target  gene would  not affect tumor cell adhesion within the peritoneal cavity. Previous in vitro and in vivo studies  n  our  laboratory  have  shown  effective  knockdown  for  up  to  72  hours following  a  single  siRNA  treatment  (134).    We  therefore  treated  our  animals 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biweekly with 5 μg siRNA per mouse.  As described above, siRNA was incorporated into  the DOPC  liposome and delivered  in a 0.9% saline solution  intraperitoneally.  Expression knockdown was confirmed using quantitative PCR.  Our  laboratory has  shown  that Chitosan nanoparticles have more effective delivery  to  peripheral  nerve  endings.    Therefore,  in  order  to  achieve  optimal delivery  to  the  neurons,  the  mTrkB  siRNA  was  incorporated  in  Chitosan nanoparticles rather than DOPC. The particles were injected intravenously through the tail vein twice weekly.    







  Adrenalectomized  animals  were  received  from  Taconic  Farms.    Animals were shipped 3 days following surgery and allowed 10 additional days for recovery prior to onset of stress.   Sham surgeries were performed on age‐matched C57/B6 mice provided by M.D. Anderson department of Experimental Radiation Oncology.  Animals  were  anesthetized  using  a  ketamine‐based  anesthesia  (100  mg/kg Ketamine,  2.5  mg/kg  Xylazine,  2.5  mg/kg  Acepromazine),  and  a  dorsal  incision measuring approximately 1 cm was made on each mouse through the skin.  A flank incision was then made through the muscle layer on the right side of each animal.  Sterile cotton swabs moistened with sterile PBS were inserted into the incision and manipulated within the animal to mimic adrenalectomy surgery.   Muscle incisions were sutured using Lycril.   External skin incisions were closed using wound clips.  Post‐surgery all animals were maintained on 0.89% saline water.     For intraovarian injections animals were anesthetized with ketamine‐based anesthesia.  Flank incisions were made on the right side of the animal and the ovary located with  the  aid  of  PBS‐moistened  cotton  swabs.    1  x  106  SKOV3‐ip1 ovarian cancer  cells  were  injected  into  the  ovary  as  a  single  cell  suspension  using  a  30‐gauge hypodermic needle. Tumors were allowed 5 weeks to grow and metastasize before necropsy.    
12. Patient Sample Immunohistochemistry Human  ovarian  tumor  clinical  specimens  were  received  from  the  M.D. Anderson gynecology oncology tumor bank following approval by the Institutional 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Review  Board.    Formalin‐fixed,  paraffin‐embedded  tumors  (both  primary  and metastatic  sites)  from  67  patients  were  stained  for  Neurofilament,  Tyrosine hydroxylase,  and  BDNF.    Slides  were  placed  in  an  oven  overnight  at  65°C  and passed through xylene to remove the paraffin and were rehydrated in PBS.  Antigen retrieval was performed in a 10 mM citrate solution in the microwave at 98°C for 10  minutes  and  allowed  to  cool  to  room  temperature  over  approximately  1.5‐2 hours.    Endogenous  peroxidase  activity  was  blocked  by  incubation  in  a  3% hydrogen peroxide solution in methanol for 12 minutes.  Tissues were incubated at room  temperature  in  a  solution  of  4%  cold‐water  fish  gelatin  in  PBS  for  protein blocking.  Tissues were incubated with primary antibodies diluted in protein block temperature in a humidified chamber overnight at 4°C. Secondary antibodies were diluted in protein block and incubated on tissues for 1 hour at room temperature in a  humidified  chamber  overnight  at  4°C.  DAB  was  applied  and  development  was monitored under a light microscope to prevent over‐exposure (approximately 4‐6 minutes).    Gill’s  hematoxylin  was  used  for  10  seconds  on  samples  for  nuclear counterstain. Samples were dried and coverslipped.  Light microscopy was used for visualization  of  nerves  using  the  40x  objective.    The  20x  objective  was  used  for BDNF  visualization.    Samples  were  scored  according  to  both  percentage  and intensity of staining. 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Figure 9. Nerve Density  in human ovarian cancers. A. Representative sections  of  neurofilament  staining  in  human  ovarian  tumor  samples.  B. Overall patient survival in patients with high versus low nerve density. 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hormones would increase expression of neurotrophic factors.  I first treated several ovarian  cancer  cell  lines  with  norepinephrine  (NE),  epinephrine  (Epi), isoproterenol (a nonspecific ADRB agonist), and cortisol.  Quantitative PCR analysis showed increased expression of Nerve Growth Factor (NGF) and Glial cell‐derived neurotrophic  factor (GDNF) family members such as BDNF and artemin following stimulation with NE, isoproterenol, and, to some extent, epinephrine.  Cortisol had little  to  no  effect  on  the  neurotrophic  genes  examined,  suggesting  that  these increases  are  in  fact mediated  through  the ADRB  family  of  receptors  rather  than glucocorticoid  receptors.  NE  treatment  caused  increased  expression  in neurotrophins within 30 minutes, with peak increases seen between 3 and 6 hours post‐treatment  (Figure  10C).    To  expand  my  analysis  to  a  broader  spectrum  of neurotrophins, I used a quantitative PCR array to examine members of the NGF and GDNF families as well as other known neurotrophic factors and related receptors.  After  exposing  cells  to  NE  for  6  hours,  my  analysis  showed  upregulation  of  two genes of particular interest, BDNF and artemin (Fig 10B).   
3. Ovarian cancer cells promote neurite extension  To determine whether ovarian cancer cells are capable of promoting neurite extension,  I  utilized a neurite  extension assay  (Figure 6).   Due  to  the difficulty  in isolating and culturing neurons of the peripheral nervous system, I used the PC12 pheochromocytoma  cell  line.   When  stimulated with  Nerve  growth  factor  (NGF), 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A. Tumors  taken  from chronically  stressed mice have higher nerve density 
than tumors taken from non­stressed mice To study the biological consequences of the increased neurite extension seen in 
vitro,  I  used  a  chronic  restraint  stress  system  to  induce  adrenergic  activation  in 
vivo.  Daily  restraint  stress  has  been  shown  to  activate  the  SNS  and  stimulate production  of  catecholamines,  resulting  in  increased  tumor  growth.    Semi‐quantitative  analysis  of  immunohistochemical  staining  of  neurofilament  in  tumor samples  taken  from animals  that underwent daily restraint stress exhibit a 3‐fold increase  in  nerve  density when  compared  to  tumors  obtained  from non‐stressed control animals (Figure 12).    










C. The role of nerve density in metastasis Evaluation of patient  samples  suggested  that  tumor  innervation  is not  site specific.    To  confirm  this  observation,  I  utilized  an  intraovarian model  of  ovarian cancer metastasis with  or without  chronic  stress.    In  this model,  tumor  cells  are injected  directly  into  the  ovary  and  allowed  to  metastasize.    Tumors  were  then collected and analyzed for nerve density at the metastatic site. Nerves were seen in tumors  taken  from  spleen,  ovary,  peritoneum,  omentum,  and  liver.  As  shown  in figure  13B,  nerve  density  in  these  tissues  varies  greatly,  suggesting  that  native nerve  density  does  not  play  a  significant  role  in  predilection  of  tumors  to metastasize to certain sites.   In  the  intraovarian  model  of  ovarian  cancer  metastasis,  tumors  most frequently  metastasized  to  the  peritoneum,  surgical  wound  site  (resulting  from injections), and the mesentery.   Analysis of  tumors taken  from each of  these sites revealed that chronic stress increased nerve density in tumors from all three sites (Figure 13A), suggesting that chronic stress increases in nerve density are not site specific.  







Figure  13.  Nerve  density  of  tumors  taken  from metastatic  sites.  A. Nerve density from metastatic ovarian tumors from various sites. B. Nerve density of various tissues from non tumor‐bearing animals 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Figure 14. BDNF siRNA in SKOV3 tumors.  Relative BDNF expression by A. IHC and B. qPCR in SKOV3 tumor samples C. Average total SKOV3 tumor weight, D. tumor nodules, and E. Average nerve density per hpf in stressed versus  non  stressed  animals  that  underwent  either  adrenalectomy  or sham surgery. 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hBDNF  siRNA  treated  stressed mice  had  no  nerves  present.  Similar  results were also seen in tumors from the HeyA8 ovarian cancer cell line (Figure 15).    To demonstrate that stress‐induced tumor neo‐innervation is not an ovarian cancer‐specific phenomenon,  I  repeated  these  experiments using  the RKO human colon cancer cell line.  Upon NE stimulation in vitro, BDNF expression increases in these  cells.    In  vivo  chronic  stress  increased  tumor  weight  and  nerve  density  in these  tumors  by  2‐fold  (Figure  16),  and  as  in  the  ovarian  cancer  models,  BDNF inhibition  using  hBDNF‐targeted  siRNA  abrogated  stress  effects  on  both  tumor growth and nerve density.  Taken together, these data suggest not only that chronic stress promotes neo‐innervation of tumors, but also that tumor neo‐innervation is critical  for  chronic  stress‐induced  effects  on  tumor  growth,  and  that  BDNF production from the tumor is a crucial factor in this process.     
5. BDNF  expression  correlates  with  nerve  density  and  patient 












Figure  16.  BDNF  siRNA  in  RKO  colon  cancer.  A.  Average  total  tumor weight  and B. Average nerve density per hpf  of RKO  tumors  taken  from stressed or non‐stressed animals treated with control or BDNF siRNA 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increased  BDNF  expression  and  increased  nerve  density.  There  was  also  a significant correlation between high BDNF expression and poor outcome (p<0.001) (Figure 17B). Patients with high levels of BDNF expression survived an average of 39 months, compared with 65 months in patients expressing low levels of BDNF.   




















Figure  19.    Downstream markers  of  chronic  stress  following  BDNF 


























Figure  22.  Hexamethonium  Bromide  treatment  in  vivo.  A.  Average total  SKOV3  tumor  weight  and  B.  Average  nerve  density  per  hpf  in stressed  versus non  stressed  animals  treated with  either PBS  control  or hexamethonium Bromide. 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supports my  hypothesis  that  neurons  of  the  peripheral  nervous  system  found  in tumors may be contributing to promoting these effects.    
 
10. Circulating catecholamines do not significantly affect  tumor 
progression in mouse syngeneic model of ovarian cancer There  are  two main  pathways  downstream  of  the  central  nervous  system that  become  activated  as  our  bodies  cope  with  a  stressor.    One  pathway  is  the sympathetic  nervous  system,  which  signals  through  catecholamines  released primarily by sympathetic nerve endings.   The other pathway is the hypothalamic‐pituitary‐adrenal  axis  (Figure  1B).    This  pathway  results  in  secretion  of glucocorticoids  and  catecholamines  from  the  adrenal  glands  to  circulate systemically  in  the  blood  stream.    Though  this  is  not  the  primary  method  of secretion for catecholamines, I wished to verify that the hormones seen within the tumor tissue are in fact coming from sympathetic nerve endings, rather than being deposited  in  the  tumor  through  circulation  from  the  adrenal  gland.    To  test  this hypothesis I utilized an adrenalectomized mouse model.  Due to low survival rates in nude mice when performing adrenalectomy surgeries, I used adrenalectomized C57/B6 mice.  Our lab has previously used a line of ID8 mouse ovarian tumor cells that express high levels of VEGF for syngeneic models of chronic stress in ovarian cancer.   Expression of neurotrophins and ability to induce neurite extension were similar in this cell line to those seen with the SKOV3 human ovarian cancer cell line, 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so  I  chose  to  utilize  this  line  for  this  model.    Following  either  adrenalectomy surgery  or  sham  surgery,  adrenalectomized mice were  given  10  days  to  recover prior to the initiation of daily stress.  These animals were then treated according to our previously established model of chronic stress in vivo (Figure 8).   Total tumor weight of tumors taken from chronically stress, adrenalectomized animals was very similar to total tumor taken from chronically stress, sham surgery animals (Figure 23A).    This  result  suggests  that  stress  hormones  being  delivered  into  the  tumor from the adrenal gland play no significant role in promoting stress‐induced tumor progression.    Further  analysis  revealed  that  nerve  density  in  tumors  from  both groups was also similar (Figure 23B), suggesting that hormones  from the adrenal gland also do not play a role in initiating neo‐innervation of tumors.     
11. Norepinephrine  stimulates  BDNF  production  in  ovarian 





Figure  23.  Tumor  weight  and  nerve  density  in  tumors  of 
adrenalectomized  mice.  A.  Average  total  SKOV3  tumor  weight  and  B. Average  nerve  density  per  hpf  in  stressed  versus  non  stressed  animals that underwent either adrenalectomy or sham surgery. 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Figure  25.  Norepinephrine­induced  increases  in  BDNF  expression 




























Figure  28.  Overview  model.  Following  a  stressor,  catecholamines  are  released which then bind to the β3 adrenergic receptor on the tumor cell surface to initiate downstream signaling  through  cAMP and Epac. Activated  Jun  crosses  the nuclear membrane  to  initiate  transcription  of  BDNF  gene  expression.    BDNF  protein  is produced and secreted from the cell where it binds TrkB receptors on sympathetic nerve endings.  This activates growth and proliferation of neurons, increasing nerve density within the tumor. Increased nerve density results in higher catecholamine levels, resulting in a positive feedback loop in which nerves promote growth of the tumor through catecholamines, and tumor cells produce BDNF to support growth and survival of neurons. 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axonogenesis.  In vivo inhibition of BDNF abrogated chronic stress effects on tumor growth  and  nerve  density.  Using  adrenalectomized  models  and  in  vivo administration  of  hexamethonium  I  demonstrated  that  chronic  stress  effects  on tumor  growth  are  mediated  through  sympathetic  nerve  endings,  as  opposed  to systemic  release of  catecholamines  from the adrenal gland, or by central nervous system  control.    hTrkB  and  mTrkB  siRNA  demonstrated  that  BDNF  acts  in  a paracrine  manner,  stimulating  nerve  growth  into  tumors  which,  in  turn,  exert effects on tumor progression, rather than in an autocrine manner of self‐activation of TrkB signaling on  the  tumor cells  themselves.   Taken  together  this work  is  the first  to  demonstrate  stress‐induced  neurogenesis  in  tumors  as  well  as  the mechanism by which tumors may stimulate tumor neo‐innervation.   
2.  Future Directions 
 
A. TrkB Switch Kinase mouse model In this work I have demonstrated a link between increased BDNF production by  tumor cells and  increased neo‐innervation.   Other  studies have suggested  that BDNF signaling may promote  tumor growth  in an autocrine  fashion by activating TrkB receptors on the tumor cells.  I utilized both human and mouse TrkB targeting siRNA  to  demonstrate  that  the  growth  advantage  provided  by  this  autocrine signaling  is  insignificant  when  compared  to  paracrine  effects  through  increased 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nerve  density.    However,  further  studies  may  be  necessary  to  draw  definitive conclusions  on  this  effect.    Due  to  the  post‐natal  lethality  of  complete  TrkB knockout,  one model  that may provide  further  insight  into  this mechanism  is  the TrkB SwitchKinase mouse model available from Taconic Farms (Hudson, NY).  This model  provides  pure TrkB  inhibition by  inhibiting  kinase  function with  a  dietary additive  that  binds  to  genetically  modified  TrkB  receptor.    This  is  due  to  point mutations  in  the  ATP‐binding  pocket  of  the  kinase.  Interestingly,  this  system  is inducible  and  reversible,  providing  effective  knockout  of  TrkB  function  without mortality of the animal (136).   This model would extend our findings and provide support  for  our  findings  that,  under  conditions of  chronic  stress, BDNF exerts  its effects through recruitment of nerves rather than signaling on tumor cells.    









D. Immune impact In my experiments I used an athymic nude mouse model, with the exception of  the adrenalectomized mouse model.   These animals are  immuno‐deficient,  and allowed me to eliminate the effects that the immune system may have in promoting or blocking tumor neo‐innervation. While this allowed me to effectively study the role of stress and increased BDNF without the confounding addition of the various aspects  of  immunity,  it  also  begs  the  question  of  what  role  these  cells  may  be playing.    For  example,  cells  of  the  immune  system  produce  high  levels  of  pro‐inflammatory  cytokines  such as  IL‐6, which  can also act  as a neurotrophic  factor, promoting nerve growth and directional guidance (147‐149).   
E. Other models of chronic stress Our  lab  and many other  groups  study  the  effects  of  chronic  stress use  the well‐accepted restraint stress model of chronic stress.  This model has been shown to affect behavior,  immunity, endocrine function, neurological, and developmental processes.    It  causes activation of many pathways known to be  involved  in stress response systems, and is therefore a widely used and accepted model.   There are, however, many  other models  of  stress.    Some  groups  utilize  dozens  of  stressors, from cold, heat, and  isolation,  to swim,  fear, and predator stress.   Effects of  these various  stressors  have  yet  to  be  studied  in  the  context  of  tumor  progression.  Additionally, animals may adapt to repetitive administration of the same stressor, blunting the effects that may be seen if a different, randomized stressor were used 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each  day,  and  the  time  during  which  stress  took  place  varied.  Our  studies  have shown that stressing animals for a period greater than 3 weeks provides no further significant  increase  in  tumor  burden.    Variations  in  stressors  may  in  fact  prove chronic  stress  can  have  much  more  substantial  effects  on  tumor  growth  than current research has described.   




G. Origin of neuronal precursors My  studies  also  demonstrated  the  presence  of  neuronal  precursors  in tumors.    These  exciting  data  suggest  that  neurogenesis  may  be  taking  place  in developing tumors, in addition to axonogenesis of existing neurons.   One question that  remains  to  be  answered,  however,  is  from where  these  neuronal  precursors are recruited. In adults, neural progenitor cells are thought to exist only within the CNS  and  bone  marrow  (150).  As  neural  progenitors  in  the  CNS  are  primarily located in the hippocampus and have only been shown to migrate to 5 mm through the Rostral migratory stream,  it  is unlikely that neurons  in the tumor originate  in the  CNS.    To  provide  an  answer  on whether  these  cells may  be  coming  from  the bone marrow,  our  group  is  using  a  fluorescent mouse model.    These  animals  are C57/B6 mice which  express RFP protein.    The  animals were  irradiated  and bone marrow  transplants  were  done  with  marrow  taken  from  GFP  expressing  donor mice.    This  model  allows  us  to  differentiate  between  native  cells  from  the  host mouse  and  cells  derived  from  the  bone  marrow.    Analysis  will  use  IHC  co‐localization  studies.    Tumors  will  be  analyzed  for  expression  of  neurofilament (nerve marker)  or  doublecortin  (neuronal  precursor marker)  as well  as GFP  and RFP  protein.    Co‐localization  between  either  neurofilament  or  doublecortin  and RFP  would  signify  neurons  originate  from  the  host  animal,  most  likely  through axonogenesis  of  existing  neurons.  Conversely,  co‐localization  between neurofilament or doublecortin and GFP would represent neurons developing from 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bone marrow‐derived progenitor  cells,  and would be,  to  our  knowledge,  the  first evidence of adult neurogenesis taking place outside of the CNS. 
3. Study impact in Cancer This  work  provides  a  mechanistic  link  between  observation  that catecholamines are significantly increased locally in tumor tissue following chronic stress and how  tumors are  responsible  for promoting  this  increase. Over  the  last several  years  there  has  been  increasing  interest  into  clinical  impacts  of  chronic stress  and  potential  treatment  options.    As  previously  mentioned,  several epidemiological  studies  have  shown  that  β‐blockers  may  be  a  viable  treatment option  to  improve  patient  care.    Other  groups  are  investigating  the  impact  of psychological  intervention  and  have  demonstrated  that  this  may  also  improve patient  outcome.    This  work  demonstrates  the  critical  role  that  BDNF  plays  in promoting chronic stress effects on tumor progression.  It therefore may serve as a viable target for improving patient outcome.  
 
4. Study impact in other diseases Chronic  stress  has  long  been  associated  with  increased  risk  of cardiovascular  disease.  Several  studies  exist  showing  a  correlation  between sympathetic innervation and heart disease.  Long QT syndrome has long been seen as  a  cause  of  sudden  cardiac  death  and  cardiovascular  abnormalities  (151).    In patients  for whom β‐blockers  are  insufficient  treatment,  left  cardiac  sympathetic denervation is used to improve patient performance (151). Increased nerve density in  various  regions  of  the  heart  has  been  associated  with  several  types  of 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